Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonz, a Swiss-based supplier to the pharmaceutical and healthcare industry, has signed development and manufacturing agreement with Genmab A/S for a novel antibody drug conjugate (ADC), HuMax-TF.
Subscribe to our email newsletter
HuMax-TF is a fully human antibody targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.
As per the deal, Genmab gets development and cGMP manufacturing plan to create ADC product targeting tissue factor (TF).
Lonza will take up process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility.
The naked antibody will be conjugated by Lonza at its ADC plant in Visp, CH to a cytotoxic drug in order to form the antibody drug conjugate HuMax-TF.